Clinical practice - Fibroblast growth factor (FGF)23: A new hormone

European Journal of Pediatrics

Volumn 170, Issue 5, 2011, Pages 545-554

  Alon, Uri S ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcitriol; FGF23; Hyperphosphatemia; Hypophosphatemia; Klotho; Parathyroid hormone; Rickets

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CINACALCET; CYTOKINE ANTIBODY; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 23 ANTIBODY; KLOTHO PROTEIN; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D;

ADJUVANT THERAPY; ALBRIGHT SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE DISORDER; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIC RICKETS; BONE GROWTH; BONE MINERALIZATION; BONE SCINTISCANNING; CALCITRIOL DEFICIENCY; CALCIUM BLOOD LEVEL; CAUSE OF DEATH; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENZYME REPRESSION; FIBROUS DYSPLASIA; GENE; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPOPHOSPHATEMIA; INTESTINE ABSORPTION; KIDNEY CALCIFICATION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; NEGATIVE FEEDBACK; NEVUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUTRITIONAL DEFICIENCY; ONCOGENIC OSTEOMALACIA; OSTEOMALACIA; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PHOSPHATURIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RICKETS; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; TISSUE GROWTH; TUMOR CALCINOSIS; X LINKED HYPOPHOSPHATEMIC RICKETS;

BONE AND BONES; FIBROBLAST GROWTH FACTORS; FIBROUS DYSPLASIA OF BONE; HUMANS; KIDNEY FAILURE, CHRONIC; OSTEOMALACIA; PHOSPHORUS METABOLISM DISORDERS; RICKETS;

EID: 79955597653     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-010-1382-5     Document Type: Review

References (103)

1. A study of KRN23 in X-linked hypophosphatemia (2010) NCT 00830675. www.clinicaltrials.gov
2. Alon US (2006) Hypophosphatemic vitamin D-resistant rickets. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. American Society of Bone and Mineral Research, Washington, DC, pp 342-345
3. Alon US, Haney C, Moore WV (2010) Cinacalcet: a novel adjuvant treatment for XLH. Pediatr Nephrol 25:1907
4. Alon US, Levy-Olomucki R, Moore WV et al (2008) Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:658-664
5. Ambuhl PM, Meier D, Wolf B et al (1999) Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 34:875-883 (Pubitemid 29521704)
6. Antoniucci DM, Yamashita T, Portale AA et al (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91:3144-3149 (Pubitemid 44271770)
7. Aono Y, Yamazaki Y, Yasutake J et al (2009) Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24:1879-1888
8. Araya K, Fukumoto S, Backenroth R et al (2005) A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523-5527 (Pubitemid 41415453)
9. Arking DE, Becker DM, Yanek LR et al (2003) KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 72:1154-1161 (Pubitemid 36530003)
10. Arking DE, Krebsova A, Macek M et al (2002) Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 99:856-861 (Pubitemid 34106600)
11. Ball AM, Gillen DL, Sherrard D et al (2002) Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288:3014-3018 (Pubitemid 35471163)
12. Barsotti G, Cupisti A, Moriconi L et al (1995) Effects of reduced protein intake in rats with congenital polycystic kidney without renal failure. Contrib Nephrol 115:134-136
13. Basiratnia M, Fazel M, Lotfi M et al (2010) Subclinical atherosclerosis and related risk factors in renal transplant recipients. Pediatr Nephrol 25:343-348
14. Batsepe M, Juppner H (2008) Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 9:171-180
15. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008 (Pubitemid 350224109)
16. Benet-Pages A, Orlik P, Strom TM et al (2005) An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390 (Pubitemid 40220655)
17. Bergwitz C, Huppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D and FGF23. Annu Rev Med 61:91-104
18. Bhan I, Shah A, Holmes J et al (2006) Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int 70:1486-1494
19. Brownstein CA, Adler F, Nelson-Williams C et al (2008) A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455-3460 (Pubitemid 351723574)
20. Cai Q, Hodgeson SF, Kao PC et al (1994) Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330:1645-1649 (Pubitemid 24166865)
21. Chalew SA, Lovchik JC, Brown et al (1996) Hypophophatemia induced in mice by transplantation of a tumor-deprived cell line from a patient with oncogenic rickets. J Pediatr Endocrinol Metab 9:593-597 (Pubitemid 27023620)
22. Cruz EA, Lugon JR, Jorgetti V (2001) Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis 44:747-756
23. Economidou D, Dovas S, Papagianni A et al (2009) FGF-23 levels before and after renal transplantation. J Transpl 2009:379-382
24. Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Matab 82:674-681 (Pubitemid 27068650)
25. Econs MJ, McEnery PT, Lennon F et al (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 132p13. J Clin Invest 100:2653-2657 (Pubitemid 28007531)
26. Evenepoel P, Meijers BK, de Jonge H et al (2008) Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 3:1829-1836
27. Evenepoel P, Naesens M, Claes K et al (2007) Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7:1193-1200 (Pubitemid 46643105)
28. Eyskens B, Proesmans W, Van Damme B et al (1995) Tumour-induced rickets: a case report and review of the literature. Eur J Pediatr 154:462-464
29. Farrow EG, White KE (2010) Recent advances in renal phosphate handling. Nat Rev Nephrol 6:207-217
30. Feng JQ, Ward LM, Liu S et al (2006) Loss of DMPI causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315 (Pubitemid 44646294)
31. Ferrari SL, Bonjour JP, Rissoli R (2005) FGF-23 relationship to dietary phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519-1524
32. Finch JL, Tokumoto M, Nakamura H et al (2010) Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 298:F1315-F1322
33. Fliser D, Kollerits B, Neyer U et al (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18:2600-2608
34. Garringer HJ, Fisher C, Larsson TE et al (2006) The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91:4037-4042 (Pubitemid 44536883)
35. Gattineni J, Bates C, Twombley K et al (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophophatemia in vivo predominately via FGF receptor 1. Am J Physiol Renal Physiol 297:F282-F291. doi:10.1152/ajprenal.90742.2008
36. Gattineni J, Baum M (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 25:591-601
37. Geller JL, Khosravi A, Kelly MH et al (2007) Clinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22:931-937
38. Gore MO, Welch BJ, Geng W et al (2009) Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney Int 76:342-347. doi:10.1038/li.2008.355
39. Green J, Debby H, Lederer E et al (2001) Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 60:1182-1196 (Pubitemid 34205819)
40. Gupta A, Winer K, Econs MJ et al (2004) FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492 (Pubitemid 39244460)
41. Gutierrez O, Isakova T, Rhee E et al (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215 (Pubitemid 41716454)
42. Gutierrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592
43. Habbig S, Beck BB, Feldkotter M et al (2009) Renal allograft calcification - prevalence and etiology in pediatric patients. Am J Nephrol 30:194-200
44. Helenius I, Remes V, Salminen S et al (2006) Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, population-based study. J Bone Miner Res 21:380-387
45. 31P nuclear magnetic resonance spectroscopy. Nephrol Dial Transplant 5:62-68
46. Hoffman WE, Hueppner HW, Deyoung BR et al (2005) Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet 134:233-236
47. Ichikawa S, Imel EA, Kreiter ML et al (2007) A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2692-2701
48. Ito N, Fukumoto S, Takeuchi Y (2007) Effect of acute changes of serum phosphate on fibroblast (FGF)23 levels in humans. J Bone Miner Metab 25:419-422 (Pubitemid 350043699)
49. Ix JH, Shlipak MG, Wassel CL et al (2010) Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 25:993-997
50. Jonsson KB, Zahradnik R, Larsson T et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophophatemia. N Engl J Med 348:1656-1663 (Pubitemid 36459471)
51. Kato K, Jeanneau C, Tarp MA (2006) Polypeptide G1NAc-transferase T3 and familial tumoral calcinosis: Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370-18377 (Pubitemid 44035494)
52. Kawaguchi H, Manabe N, Miyaura C (1999) Independent impairment of osteblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 104:229-237
53. KDIGO CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1-S130
54. Kobayashi K, Imanishi Y, Koshiyama H et al (2006) Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 78:2295-2301
55. Kuro-o M (2010) Overview of the FGF23-Klotho axis. Pediatr Nephrol 25:583-590
56. Kuro-o M, Matsumura Y, Aizawa H (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51 (Pubitemid 27494749)
57. Kurosu H, Yamamoto M, Clark JD et al (2005) Suppression of aging in mice by the hormone Klotho. Science 309:1829-1833 (Pubitemid 41325087)
58. Larsson T, Yu X, Davis SI et al (2008) A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427 (Pubitemid 40586293)
59. Levi M (2001) Post-transplant hypophosphatemia. Kidney Int 59:2377-2387
60. Liu S, Tang W, Zhou J et al (2007) Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293:E1636-E1644 (Pubitemid 350255114)
61. Lopez V, Toledo R, Sola E et al (2009) Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 41:2394-2395
62. Lorenz-Depiereux B, Bastepe M, Benet-Pages et al (2006) DMPI mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250 (Pubitemid 44646286)
63. Lyles KW, Burkes EJ, Ellis GJ et al (1985) Genetic transmission of tumoral calcinosis: autosomal dominate with variable clinical expressivity. J Clin Endocrinol Metab 60:1093-1096 (Pubitemid 15064764)
64. Mirza MA, Hansen T, Johansson L et al (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24:3125-3131
65. Mirza MA, Larsson A, Melhus H (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546-551
66. Moe SM, Chen NX, Seifert MF et al (2009) A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75:176-184
67. Nagano N, Miyata S, Abe M et al (2006) Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Inter 69:425-427
68. Nakatani T, Sarraj B, Ohnishi M (2009) In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (FGF23)- mediated regulation of systemic phosphate homeostasis. FASEB J 23:433-441
69. Narayanan K, Ramachandran A, Hao J et al (2003) Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem 278:17500-17508 (Pubitemid 36799637)
70. Oliveira RB, Cancela AL, Graciolli FG et al (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5:286-291
71. Parfitt AM, Kleerekoper M, Cruz C (1986) Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: implications for the pathogenesis of hyperparathyroidism in chronic renal failure. Miner Electrolyte Metab 12:356-362 (Pubitemid 17002644)
72. Pattaragarn A, Alon US (2001) Antacid-induced rickets in infancy. Clin Pediatr 40:389-393 (Pubitemid 32634884)
73. Pinheiro HS, Camara NO, Osaki KS et al (2005) Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. Am J Transplant 5:323-329 (Pubitemid 40179519)
74. Prie D, Friedlander G (2010) Genetic disorders of renal phosphate transport. N Engl J Med 362:2399-2409
75. Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820-3828
76. Riminucci M, Collins M, Fedark N et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692 (Pubitemid 38057709)
77. +-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 278:2206-2211
78. Saito H, Maeda A, Ohtomo S (2005) Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543-2549 (Pubitemid 40189356)
79. Sanjad SA, Ibrahim A, Al Shorafa S et al (2001) Renal tubular dysfunction following kidney transplantation: a prospective study in 31 children. Transplant Proc 33:2830-2831 (Pubitemid 32725907)
80. Seeherunvong W, Abitbol C, Chandar J et al (2010) Fibroblast growth factor 23 (FGF23) and left ventricular hypertrophy (LVH) in children on dialysis. Abstract submitted to the American Society of Nephrology
81. Serra AL, Wuhrmann C, Wuthrich RP (2008) Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 52:1151-1157
82. Shigematsu T, Kazama JJ, Yamashita T et al (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250-256 (Pubitemid 38962552)
83. Shimada T, Hasegawa Y, Yamazaki Y (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostatsis. J Bone Miner Res 19:429-435 (Pubitemid 38787398)
84. Shimada T, Kakitani M, Yamazaki Y (2004) Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568 (Pubitemid 38542505)
85. Shimada T, Mizutani S, Muto T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505 (Pubitemid 32488266)
86. Shimada T, Yamazaki Y, Takahashi M et al (2005) Vitamin D receptor-independent FGF23 actions in regulation phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088-F1095 (Pubitemid 41447065)
87. Tenenhouse HS, Econs MH (2001) Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valley D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 5039-5067
88. Tiosana D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392-401
89. Topaz O, Shurman DL, Bergman R et al (2004) Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581 (Pubitemid 38715983)
90. United States Renal Data System. Annual data report 2009, vol 2. Chapter 7: Transplantation. "http://wwwusrdsorg/2009/pdf/V2-07-09PDF" http://wwwusrdsorg/2009/pdf/V2-07-09PDF, accessed 1 June 2010
91. Urakawa I, Yamazaki Y, Shimada T et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774 (Pubitemid 44949607)
92. Valta H, Makitie O, Ronnholm K (2009) Bone health in children and adolescents after renal transplantation. J Bone Miner Res 24:1699-1708
93. van Husen M, Fischer AK, Lehnhardt A et al (2010) Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 78:200-206
94. Weber TJ, Liu S, Indridason OS et al (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234 (Pubitemid 37294915)
95. White KE, Evans WE, O'Riordan JL (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
96. White KE, Evans WE, O'Riordan JLH et al (2000) Autosomal dominant hypophophatemic rickets is associated with mutations in FGF23. Nat Genet 26:345-248
97. Wilson AC, Greenbaum LA, Barletta GM et al (2010) High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant 14:52-60
98. Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:427-1435
99. Yamamoto T, Imanishi Y, Kinoshita E et al (2005) The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 23:231-237 (Pubitemid 40603206)
100. Yamashita T, Yoshioka M, Itoh N et al (2000) Identification of a novel fibroblast growth factor, FGF23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494-498
101. Yamazaki Y, Okazaki R, Shibata M et al (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960 (Pubitemid 35316332)
102. Yamazaki Y, Tamada T, Kasai N et al (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509-1518
103. Yu X, Sabbagh Y, Davis SI et al (2005) Genetic dissection of phosphate- and vitamin D-mediated regulation of circulation FGF23 concentrations. Bone 36:971-977 (Pubitemid 40797997)